Understand the source comparison
Evidence Quality — Preclinical vs Clinical Data and What It Means
The evidence base for peptide-based memory enhancement spans three tiers: in vitro receptor binding studies, animal behavioural models, and human clinical trials. Most compounds marketed as cognitive enhancers never progress beyond tier one. Receptor binding d
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The evidence base for peptide-based memory enhancement spans three tiers: in vitro receptor binding studies, animal behavioural models, and human clinical trials. Most compounds marketed as cognitive enhancers never progress beyond tier one. Receptor binding data alone doesn't prove CNS efficacy or functional benefit.
- Semax has completed multiple human trials in Russia and Eastern Europe, including a 2015 randomised controlled trial in healthy adults showing improved delayed recall performance (16% improvement vs placebo) and reduced reaction time in attention tasks. The trial used intranasal administration at 600mcg twice daily for 14 days. A dose range that achieved measurable plasma levels without significant adverse events. That's tier-three evidence: demonstrated cognitive benefit in the target population with a defined dosing protocol.
- Cerebrolysin's evidence base is more extensive but also more contested. Meta-analyses of Cerebrolysin trials in vascular dementia show modest but statistically significant cognitive improvements (standardised mean difference of 0.25–0.35 on ADAS-Cog scales), but concerns about publication bias and trial quality persist. The mechanism is biologically plausible. Delivering neurotrophic peptides directly bypasses the blood-brain barrier limitation that constrains oral supplements. But the clinical effect size is smaller than many advocates claim.
- Dihexa remains entirely in preclinical development as of 2026. No published human trials exist. The animal data is striking (7× more potent than BDNF in promoting synaptogenesis), but translating rodent memory task performance to human cognitive benefit is notoriously unreliable. Until Phase I safety data emerges, Dihexa's real-world efficacy in humans is speculative.
- Our team's experience with research-grade peptide evaluation consistently shows this pattern: compounds with documented CNS penetration and receptor-level activity demonstrate measurable cognitive effects in controlled settings, while those marketed based solely on in vitro data rarely produce clinically meaningful benefits. The difference is mechanism specificity. Knowing exactly which receptor a peptide binds to and what downstream signalling cascade that activates.